RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $6

Benzinga ·  11/09/2023 03:22

RBC Capital analyst Gregory Renza maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target from $7 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment